Working to Eradicate Gynecologic Cancers

SEM
Seminal Abstract Session - Role of Anti-angiogenic agents in Ovarian Cancer

Tuesday, March 25, 2014: 9:10 AM-10:25 AM
Ballroom B/C (Tampa Convention Center)
Description: The SGO Program Committee selected important seminal studies to be presented during SGO from other National and International meetings. All seminal abstracts were previously presented at the ESMO Annual Meeting, Amsterdam, Netherlands - 27 Sep - 01 Oct 2013. For full abstract details, go to http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx
Moderator:  Robert Scott Mannel, MD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
9:10 AM
Moderator Introductions
R. S. Mannel
University of Oklahoma Health Sciences Center, Oklahoma City, OK
 
9:15 AM
2 - Seminal Abstract
ICON 7: Final overall survival results in teh GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer
A. M. Oza1, T. J. Perren2, A. M. Swart3, W. Schröder4, E. Pujade-Lauraine5, H. Havsteen6, P. J. Beale7, G. Cervantes8, A. C. Embleton9 and M. Parmar10
1University Health Network, Princess Margaret Hospital, Toronto, ON, Canada, 2St James Hospital, St. James’s Institute of Oncology, Leeds, United Kingdom, 3MRC/NCRI (Medical Research Council/National Cancer Research Institute), London, United Kingdom, 4GYNAEKOLOGICUM BREMEN, Bremen, Germany, 5Hopital Hotel Dieu, Paris, France, 6Herlev Hospital, Oncology, Herlev, Denmark, 7Royal Prince Alfred Hospital, Camperdown, Australia, 8Issste Hospital, Mexico City, DF, Mexico, 9Newcastle University, Newcastle, United Kingdom, 10Medical Research Council Clinical Trials, London, England
 
9:25 AM
3 - Seminal Abstract
Randomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum-sensitive ovarian cancer: results of the ICON6 trial
H. W. Hirte
McMaster University, Hamilton, ON, Canada
 
9:35 AM
4 - Seminal Abstract
A phase III, randomized, double-blind trialof weekly paclitaxel plus the angiopoientin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1
B. J. Monk1, A. Poveda2, I. B. Vergote3, F. Raspagliesi4, K. Fujiwara5, D. S. Bae6, A. Oaknin7, L. Navale8, D. J. Warner8 and A. M. Oza9
1University of Arizona Cancer Center, Phoenix, AZ, 2Fundación Instituto Valenciano de Oncología, Valencia, Spain, 3University Hospital Leuven, Leuven, Belgium, 4Fondazione IRCCS Istituto Nazionale Tumori -Milan, Milan, Italy, 5Saitama Medical University International Medical Center, Hidaka-Shi, Japan, 6Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 7GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, 8Amgen Inc., Thousand Oaks, CA, 9University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
 
9:45 AM
Lecturette: Overview of Current Anti-Angiogenesis
R. L. Coleman
The University of Texas MD Anderson Cancer Center, Houston, TX
 
9:55 AM
Audience Participation and ARS Voting
 
9:57 AM
Debate: Costs and Quality of Life: Anti Angiogenesis Agents Should be Used Earlier in Treatment
B. J. Monk
University of Arizona Cancer Center, Phoenix, AZ
 
10:04 AM
Debate: Costs and Quality of Life: Anti Angiogenesis Agents Should be reserved for patients with Platinum Resistant Disease
D. E. Cohn
The Ohio State University, Columbus, OH
 
10:11 AM
Audience Participation and ARS Voting
 
10:16 AM
Question & Answer
 
See more of: Seminal Session
<< Previous Course | Next Course >>